Health ❯ Healthcare ❯ Pharmaceuticals

Drug Regulation

FDA FDA Decisions Mifepristone FDA Actions FDA Leadership Counterfeit Drugs Compounding Pharmacies Illicit Drugs Alzheimer's Disease FDA Enforcement Compounded Medications Hormone Replacement Therapy European Medicines Agency Counterfeit Medications Indian Pharmacopoeia Prohibited Medications Illegal Drugs Pharmacy Benefit Managers Drug Importation Fake Medicines Contamination Issues Contaminated Drugs CDSCO ANMAT Guidelines Traceability Systems Opioid Medications GLP-1 Drugs FDA Guidelines Traceability Issues Nonopioid Treatments Illegal Sales Antibiotic Classification FDA Warning Letters Veterinary Medicine FDA Regulations Quality Control Vaccine Development Contaminated Products Imported Drugs Central Drugs Standard Control Organisation ANMAT Actions Anti-Obesity Treatments Prescription Medicines Cough Syrups Public Health Concerns Hormone Therapy Alzheimer's Treatment Patent Law Alzheimer's Therapy Weight Loss Medications Access to Medication FDA Recall Interchangeability of Medications FDA Oversight Psychedelic Treatments Online Pharmacies Weight-loss Injections Unlicensed Drugs Manufacturer Recalls Fixed-Dose Combination Drugs Fixed Dose Combinations

FDA Installs Tracy Beth Hoeg as Acting CDER Director as Pazdur Files Retirement

The acting appointment underscores internal rifts over rapid‑review plans that have unsettled stakeholders.

FDA Names Richard Pazdur to Lead Drug Review Center

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Senate Democrats Press FDA on Mifepristone Review After Court Strikes Down Restrictions

FDA Issues Warning Letters to 18 Websites Selling Unapproved Botox-Like Injectables

FDA Class II Recall Targets 580,000 Prazosin Bottles for Nitrosamine Overages

Pittsburgh Weight-Loss Clinic Operator Charged Over Veterinary hCG as Guilty Plea Set for Nov. 18

Experts Press to Include Pregnant People in Drug Trials After Tylenol–Autism Claims

Ascend Recalls 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

GOP Senators Move to Curb Mifepristone After FDA Clears Second Generic

Former FDA Biologics Chief Peter Marks Joins Eli Lilly to Lead Infectious Disease and Molecule Discovery

FDA Signals Possible Revisions to Menopause Hormone Therapy Black Box Warning

FDA Posts More Than 100 Warning Letters in Drug Ad Crackdown, Targeting Hims, Lilly and Novo

FDA Publishes Draft Guidance for Non-Opioid Analgesics to Treat Chronic Pain

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research